APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Peptide APIs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Therapeutic Peptide APIs Industry Research Report 2026

27 December 2025146 pages

Choose your research edition.

Industry ResearchTherapeutic Peptide APIs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Peptide APIs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal Therapeutic Peptide APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Peptide APIs Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Peptide APIs Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Therapeutic Peptide APIs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Therapeutic Peptide APIs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Therapeutic Peptide APIs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Therapeutic Peptide APIs include AmbioPharm, Aspen API, Bachem, Bio Basic, CordenPharma, CPC Scientific, GenScript, JPT Peptide Technologies and Limitless Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Therapeutic Peptide APIs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Therapeutic Peptide APIs Market by Company

AmbioPharm

Aspen API

Bachem

Bio Basic

CordenPharma

CPC Scientific

GenScript

JPT Peptide Technologies

Limitless Biotech

Lonza

Piramal Pharma

PolyPeptide

ScinoPharm

Syngene

USV Peptides

Hybio Pharmaceutical

Guangdong Jianyuan Pharmaceutical

Jiangsu Sinopep-Allsino Biopharmaceutical

Zhejiang Peptites Biotech

Cheng Du Sheng Nuo Biotec

Hainan Shuangcheng Pharmaceuticals

Therapeutic Peptide APIs Segment by Type

Bioactive Peptides

Synthetic Peptides

Therapeutic Peptide APIs Segment by Application

Pharmaceuticals

Scientific Research

Other

Therapeutic Peptide APIs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide APIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Therapeutic Peptide APIs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Therapeutic Peptide APIs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Therapeutic Peptide APIs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Therapeutic Peptide APIs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Therapeutic Peptide APIs Sales (Tons) of Manufacturers (2021-2026) Table 7. Global Therapeutic Peptide APIs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Therapeutic Peptide APIs Revenue of Manufacturers (2021-2026) Table 9. Global Therapeutic Peptide APIs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Therapeutic Peptide APIs Average Price (US$/K G) of Manufacturers (2021-2026) Table 11. Global Therapeutic Peptide APIs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Therapeutic Peptide APIs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Therapeutic Peptide APIs, Product Type & Application Table 14. Global Therapeutic Peptide APIs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Therapeutic Peptide APIs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. AmbioPharm Company Information Table 19. AmbioPharm Business Overview Table 20. AmbioPharm Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 21. AmbioPharm Therapeutic Peptide APIs Product Portfolio Table 22. AmbioPharm Recent Developments Table 23. Aspen API Company Information Table 24. Aspen API Business Overview Table 25. Aspen API Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 26. Aspen API Therapeutic Peptide APIs Product Portfolio Table 27. Aspen API Recent Developments Table 28. Bachem Company Information Table 29. Bachem Business Overview Table 30. Bachem Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 31. Bachem Therapeutic Peptide APIs Product Portfolio Table 32. Bachem Recent Developments Table 33. Bio Basic Company Information Table 34. Bio Basic Business Overview Table 35. Bio Basic Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 36. Bio Basic Therapeutic Peptide APIs Product Portfolio Table 37. Bio Basic Recent Developments Table 38. CordenPharma Company Information Table 39. CordenPharma Business Overview Table 40. CordenPharma Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 41. CordenPharma Therapeutic Peptide APIs Product Portfolio Table 42. CordenPharma Recent Developments Table 43. CPC Scientific Company Information Table 44. CPC Scientific Business Overview Table 45. CPC Scientific Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 46. CPC Scientific Therapeutic Peptide APIs Product Portfolio Table 47. CPC Scientific Recent Developments Table 48. GenScript Company Information Table 49. GenScript Business Overview Table 50. GenScript Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 51. GenScript Therapeutic Peptide APIs Product Portfolio Table 52. GenScript Recent Developments Table 53. JPT Peptide Technologies Company Information Table 54. JPT Peptide Technologies Business Overview Table 55. JPT Peptide Technologies Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 56. JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio Table 57. JPT Peptide Technologies Recent Developments Table 58. Limitless Biotech Company Information Table 59. Limitless Biotech Business Overview Table 60. Limitless Biotech Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 61. Limitless Biotech Therapeutic Peptide APIs Product Portfolio Table 62. Limitless Biotech Recent Developments Table 63. Lonza Company Information Table 64. Lonza Business Overview Table 65. Lonza Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 66. Lonza Therapeutic Peptide APIs Product Portfolio Table 67. Lonza Recent Developments Table 68. Piramal Pharma Company Information Table 69. Piramal Pharma Business Overview Table 70. Piramal Pharma Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 71. Piramal Pharma Therapeutic Peptide APIs Product Portfolio Table 72. Piramal Pharma Recent Developments Table 73. PolyPeptide Company Information Table 74. PolyPeptide Business Overview Table 75. PolyPeptide Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 76. PolyPeptide Therapeutic Peptide APIs Product Portfolio Table 77. PolyPeptide Recent Developments Table 78. ScinoPharm Company Information Table 79. ScinoPharm Business Overview Table 80. ScinoPharm Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 81. ScinoPharm Therapeutic Peptide APIs Product Portfolio Table 82. ScinoPharm Recent Developments Table 83. Syngene Company Information Table 84. Syngene Business Overview Table 85. Syngene Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 86. Syngene Therapeutic Peptide APIs Product Portfolio Table 87. Syngene Recent Developments Table 88. USV Peptides Company Information Table 89. USV Peptides Business Overview Table 90. USV Peptides Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 91. USV Peptides Therapeutic Peptide APIs Product Portfolio Table 92. USV Peptides Recent Developments Table 93. Hybio Pharmaceutical Company Information Table 94. Hybio Pharmaceutical Business Overview Table 95. Hybio Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 96. Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 97. Hybio Pharmaceutical Recent Developments Table 98. Guangdong Jianyuan Pharmaceutical Company Information Table 99. Guangdong Jianyuan Pharmaceutical Business Overview Table 100. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 101. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 102. Guangdong Jianyuan Pharmaceutical Recent Developments Table 103. Jiangsu Sinopep-Allsino Biopharmaceutical Company Information Table 104. Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview Table 105. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 106. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio Table 107. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments Table 108. Zhejiang Peptites Biotech Company Information Table 109. Zhejiang Peptites Biotech Business Overview Table 110. Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 111. Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio Table 112. Zhejiang Peptites Biotech Recent Developments Table 113. Cheng Du Sheng Nuo Biotec Company Information Table 114. Cheng Du Sheng Nuo Biotec Business Overview Table 115. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 116. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio Table 117. Cheng Du Sheng Nuo Biotec Recent Developments Table 118. Hainan Shuangcheng Pharmaceuticals Company Information Table 119. Hainan Shuangcheng Pharmaceuticals Business Overview Table 120. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales (Tons), Revenue (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 121. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio Table 122. Hainan Shuangcheng Pharmaceuticals Recent Developments Table 123. Global Therapeutic Peptide APIs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 124. Global Therapeutic Peptide APIs Sales by Region (2021-2026) & (Tons) Table 125. Global Therapeutic Peptide APIs Sales Market Share by Region (2021-2026) Table 126. Global Therapeutic Peptide APIs Sales by Region (2027-2032) & (Tons) Table 127. Global Therapeutic Peptide APIs Sales Market Share by Region (2027-2032) Table 128. Global Therapeutic Peptide APIs Revenue by Region (2021-2026) & (US$ Million) Table 129. Global Therapeutic Peptide APIs Revenue Market Share by Region (2021-2026) Table 130. Global Therapeutic Peptide APIs Revenue by Region (2027-2032) & (US$ Million) Table 131. Global Therapeutic Peptide APIs Revenue Market Share by Region (2027-2032) Table 132. North America Therapeutic Peptide APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. North America Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 134. North America Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 135. North America Therapeutic Peptide APIs Revenue by Country (2021-2026) & (US$ Million) Table 136. North America Therapeutic Peptide APIs Revenue by Country (2027-2032) & (US$ Million) Table 137. Europe Therapeutic Peptide APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Europe Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 139. Europe Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 140. Europe Therapeutic Peptide APIs Revenue by Country (2021-2026) & (US$ Million) Table 141. Europe Therapeutic Peptide APIs Revenue by Country (2027-2032) & (US$ Million) Table 142. Asia Pacific Therapeutic Peptide APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Asia Pacific Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 144. Asia Pacific Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 145. Asia Pacific Therapeutic Peptide APIs Revenue by Country (2021-2026) & (US$ Million) Table 146. Asia Pacific Therapeutic Peptide APIs Revenue by Country (2027-2032) & (US$ Million) Table 147. South America Therapeutic Peptide APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. South America Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 149. South America Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 150. South America Therapeutic Peptide APIs Revenue by Country (2021-2026) & (US$ Million) Table 151. South America Therapeutic Peptide APIs Revenue by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Therapeutic Peptide APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Middle East and Africa Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 154. Middle East and Africa Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 155. Middle East and Africa Therapeutic Peptide APIs Revenue by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Therapeutic Peptide APIs Revenue by Country (2027-2032) & (US$ Million) Table 157. Global Therapeutic Peptide APIs Sales by Type (2021-2026) & (Tons) Table 158. Global Therapeutic Peptide APIs Sales by Type (2027-2032) & (Tons) Table 159. Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2026) Table 160. Global Therapeutic Peptide APIs Sales Market Share by Type (2027-2032) Table 161. Global Therapeutic Peptide APIs Revenue by Type (2021-2026) & (US$ Million) Table 162. Global Therapeutic Peptide APIs Revenue by Type (2027-2032) & (US$ Million) Table 163. Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2026) Table 164. Global Therapeutic Peptide APIs Revenue Market Share by Type (2027-2032) Table 165. Global Therapeutic Peptide APIs Price by Type (2021-2026) & (US$/K G) Table 166. Global Therapeutic Peptide APIs Price by Type (2027-2032) & (US$/K G) Table 167. Global Therapeutic Peptide APIs Sales by Application (2021-2026) & (Tons) Table 168. Global Therapeutic Peptide APIs Sales by Application (2027-2032) & (Tons) Table 169. Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2026) Table 170. Global Therapeutic Peptide APIs Sales Market Share by Application (2027-2032) Table 171. Global Therapeutic Peptide APIs Revenue by Application (2021-2026) & (US$ Million) Table 172. Global Therapeutic Peptide APIs Revenue by Application (2027-2032) & (US$ Million) Table 173. Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2026) Table 174. Global Therapeutic Peptide APIs Revenue Market Share by Application (2027-2032) Table 175. Global Therapeutic Peptide APIs Price by Application (2021-2026) & (US$/K G) Table 176. Global Therapeutic Peptide APIs Price by Application (2027-2032) & (US$/K G) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Therapeutic Peptide APIs Distributors List Table 180. Therapeutic Peptide APIs Customers List Table 181. Therapeutic Peptide APIs Industry Trends Table 182. Therapeutic Peptide APIs Industry Drivers Table 183. Therapeutic Peptide APIs Industry Restraints Table 184. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Therapeutic Peptide APIs Product Image Figure 5. Global Therapeutic Peptide APIs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Therapeutic Peptide APIs Market Size (2021-2032) & (US$ Million) Figure 7. Global Therapeutic Peptide APIs Sales (2021-2032) & (Tons) Figure 8. Global Therapeutic Peptide APIs Average Price (US$/K G) & (2021-2032) Figure 9. Bioactive Peptides Product Image Figure 10. Synthetic Peptides Product Image Figure 11. Pharmaceuticals Product Image Figure 12. Scientific Research Product Image Figure 13. Other Product Image Figure 14. Global Therapeutic Peptide APIs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Therapeutic Peptide APIs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Therapeutic Peptide APIs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Therapeutic Peptide APIs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Therapeutic Peptide APIs Sales by Region in 2025 Figure 20. Global Therapeutic Peptide APIs Revenue by Region in 2025 Figure 21. North America Therapeutic Peptide APIs Market Size by Country in 2025 Figure 22. North America Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 23. North America Therapeutic Peptide APIs Revenue Market Share by Country (2021-2032) Figure 24. United States Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Therapeutic Peptide APIs Market Size by Country in 2025 Figure 27. Europe Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 28. Europe Therapeutic Peptide APIs Revenue Market Share by Country (2021-2032) Figure 29. Germany Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Therapeutic Peptide APIs Market Size by Country in 2025 Figure 40. Asia Pacific Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Therapeutic Peptide APIs Revenue Market Share by Country (2021-2032) Figure 42. China Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Therapeutic Peptide APIs Market Size by Country in 2025 Figure 51. South America Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 52. South America Therapeutic Peptide APIs Revenue Market Share by Country (2021-2032) Figure 53. Brazil Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Therapeutic Peptide APIs Market Size by Country in 2025 Figure 57. Middle East and Africa Therapeutic Peptide APIs Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Therapeutic Peptide APIs Revenue Market Share by Country (2021-2032) Figure 59. Egypt Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries Therapeutic Peptide APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2032) Figure 65. Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2032) Figure 66. Global Therapeutic Peptide APIs Price (US$/K G) by Type (2021-2032) Figure 67. Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2032) Figure 68. Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2032) Figure 69. Global Therapeutic Peptide APIs Price (US$/K G) by Application (2021-2032) Figure 70. Therapeutic Peptide APIs Value Chain Figure 71. Therapeutic Peptide APIs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Therapeutic Peptide APIs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Bioactive Peptides
  • Synthetic Peptides
Applications
  • Pharmaceuticals
  • Scientific Research
  • Other
Companies covered
  • AmbioPharm
  • Aspen API
  • Bachem
  • Bio Basic
  • CordenPharma
  • CPC Scientific
  • GenScript
  • JPT Peptide Technologies
  • Limitless Biotech
  • Lonza
  • Piramal Pharma
  • PolyPeptide
  • ScinoPharm
  • Syngene
  • USV Peptides
  • Hybio Pharmaceutical
  • Guangdong Jianyuan Pharmaceutical
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • Zhejiang Peptites Biotech
  • Cheng Du Sheng Nuo Biotec
  • Hainan Shuangcheng Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Therapeutic Peptide APIs Market Size (2021-2032)
  4. 2.2.2 Global Therapeutic Peptide APIs Sales (2021-2032)
  5. 2.2.3 Global Therapeutic Peptide APIs Market Average Price (2021-2032)
  6. 2.3 Therapeutic Peptide APIs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Bioactive Peptides
  9. 2.3.3 Synthetic Peptides
  10. 2.4 Therapeutic Peptide APIs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Pharmaceuticals
  13. 2.4.3 Scientific Research
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Therapeutic Peptide APIs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Therapeutic Peptide APIs Sales (Tons) of Manufacturers (2021-2026)
  3. 3.3 Global Therapeutic Peptide APIs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Therapeutic Peptide APIs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Therapeutic Peptide APIs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Therapeutic Peptide APIs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Therapeutic Peptide APIs, Product Type & Application
  8. 3.8 Global Manufacturers of Therapeutic Peptide APIs, Established Date
  9. 3.9 Global Therapeutic Peptide APIs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 AmbioPharm
  2. 4.1.1 AmbioPharm Company Information
  3. 4.1.2 AmbioPharm Business Overview
  4. 4.1.3 AmbioPharm Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 AmbioPharm Therapeutic Peptide APIs Product Portfolio
  6. 4.1.5 AmbioPharm Recent Developments
  7. 4.2 Aspen API
  8. 4.2.1 Aspen API Company Information
  9. 4.2.2 Aspen API Business Overview
  10. 4.2.3 Aspen API Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Aspen API Therapeutic Peptide APIs Product Portfolio
  12. 4.2.5 Aspen API Recent Developments
  13. 4.3 Bachem
  14. 4.3.1 Bachem Company Information
  15. 4.3.2 Bachem Business Overview
  16. 4.3.3 Bachem Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bachem Therapeutic Peptide APIs Product Portfolio
  18. 4.3.5 Bachem Recent Developments
  19. 4.4 Bio Basic
  20. 4.4.1 Bio Basic Company Information
  21. 4.4.2 Bio Basic Business Overview
  22. 4.4.3 Bio Basic Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bio Basic Therapeutic Peptide APIs Product Portfolio
  24. 4.4.5 Bio Basic Recent Developments
  25. 4.5 CordenPharma
  26. 4.5.1 CordenPharma Company Information
  27. 4.5.2 CordenPharma Business Overview
  28. 4.5.3 CordenPharma Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CordenPharma Therapeutic Peptide APIs Product Portfolio
  30. 4.5.5 CordenPharma Recent Developments
  31. 4.6 CPC Scientific
  32. 4.6.1 CPC Scientific Company Information
  33. 4.6.2 CPC Scientific Business Overview
  34. 4.6.3 CPC Scientific Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 CPC Scientific Therapeutic Peptide APIs Product Portfolio
  36. 4.6.5 CPC Scientific Recent Developments
  37. 4.7 GenScript
  38. 4.7.1 GenScript Company Information
  39. 4.7.2 GenScript Business Overview
  40. 4.7.3 GenScript Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GenScript Therapeutic Peptide APIs Product Portfolio
  42. 4.7.5 GenScript Recent Developments
  43. 4.8 JPT Peptide Technologies
  44. 4.8.1 JPT Peptide Technologies Company Information
  45. 4.8.2 JPT Peptide Technologies Business Overview
  46. 4.8.3 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio
  48. 4.8.5 JPT Peptide Technologies Recent Developments
  49. 4.9 Limitless Biotech
  50. 4.9.1 Limitless Biotech Company Information
  51. 4.9.2 Limitless Biotech Business Overview
  52. 4.9.3 Limitless Biotech Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Limitless Biotech Therapeutic Peptide APIs Product Portfolio
  54. 4.9.5 Limitless Biotech Recent Developments
  55. 4.10 Lonza
  56. 4.10.1 Lonza Company Information
  57. 4.10.2 Lonza Business Overview
  58. 4.10.3 Lonza Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lonza Therapeutic Peptide APIs Product Portfolio
  60. 4.10.5 Lonza Recent Developments
  61. 4.11 Piramal Pharma
  62. 4.11.1 Piramal Pharma Company Information
  63. 4.11.2 Piramal Pharma Business Overview
  64. 4.11.3 Piramal Pharma Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Piramal Pharma Therapeutic Peptide APIs Product Portfolio
  66. 4.11.5 Piramal Pharma Recent Developments
  67. 4.12 PolyPeptide
  68. 4.12.1 PolyPeptide Company Information
  69. 4.12.2 PolyPeptide Business Overview
  70. 4.12.3 PolyPeptide Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 PolyPeptide Therapeutic Peptide APIs Product Portfolio
  72. 4.12.5 PolyPeptide Recent Developments
  73. 4.13 ScinoPharm
  74. 4.13.1 ScinoPharm Company Information
  75. 4.13.2 ScinoPharm Business Overview
  76. 4.13.3 ScinoPharm Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 ScinoPharm Therapeutic Peptide APIs Product Portfolio
  78. 4.13.5 ScinoPharm Recent Developments
  79. 4.14 Syngene
  80. 4.14.1 Syngene Company Information
  81. 4.14.2 Syngene Business Overview
  82. 4.14.3 Syngene Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Syngene Therapeutic Peptide APIs Product Portfolio
  84. 4.14.5 Syngene Recent Developments
  85. 4.15 USV Peptides
  86. 4.15.1 USV Peptides Company Information
  87. 4.15.2 USV Peptides Business Overview
  88. 4.15.3 USV Peptides Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 USV Peptides Therapeutic Peptide APIs Product Portfolio
  90. 4.15.5 USV Peptides Recent Developments
  91. 4.16 Hybio Pharmaceutical
  92. 4.16.1 Hybio Pharmaceutical Company Information
  93. 4.16.2 Hybio Pharmaceutical Business Overview
  94. 4.16.3 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  96. 4.16.5 Hybio Pharmaceutical Recent Developments
  97. 4.17 Guangdong Jianyuan Pharmaceutical
  98. 4.17.1 Guangdong Jianyuan Pharmaceutical Company Information
  99. 4.17.2 Guangdong Jianyuan Pharmaceutical Business Overview
  100. 4.17.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  102. 4.17.5 Guangdong Jianyuan Pharmaceutical Recent Developments
  103. 4.18 Jiangsu Sinopep-Allsino Biopharmaceutical
  104. 4.18.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
  105. 4.18.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
  106. 4.18.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio
  108. 4.18.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
  109. 4.19 Zhejiang Peptites Biotech
  110. 4.19.1 Zhejiang Peptites Biotech Company Information
  111. 4.19.2 Zhejiang Peptites Biotech Business Overview
  112. 4.19.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio
  114. 4.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 4.20 Cheng Du Sheng Nuo Biotec
  116. 4.20.1 Cheng Du Sheng Nuo Biotec Company Information
  117. 4.20.2 Cheng Du Sheng Nuo Biotec Business Overview
  118. 4.20.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio
  120. 4.20.5 Cheng Du Sheng Nuo Biotec Recent Developments
  121. 4.21 Hainan Shuangcheng Pharmaceuticals
  122. 4.21.1 Hainan Shuangcheng Pharmaceuticals Company Information
  123. 4.21.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  124. 4.21.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio
  126. 4.21.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
5 Global Therapeutic Peptide APIs Market Scenario by Region
  1. 5.1 Global Therapeutic Peptide APIs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Therapeutic Peptide APIs Sales by Region: 2021-2032
  3. 5.2.1 Global Therapeutic Peptide APIs Sales by Region: 2021-2026
  4. 5.2.2 Global Therapeutic Peptide APIs Sales by Region: 2027-2032
  5. 5.3 Global Therapeutic Peptide APIs Revenue by Region: 2021-2032
  6. 5.3.1 Global Therapeutic Peptide APIs Revenue by Region: 2021-2026
  7. 5.3.2 Global Therapeutic Peptide APIs Revenue by Region: 2027-2032
  8. 5.4 North America Therapeutic Peptide APIs Market Facts & Figures by Country
  9. 5.4.1 North America Therapeutic Peptide APIs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Therapeutic Peptide APIs Sales by Country (2021-2032)
  11. 5.4.3 North America Therapeutic Peptide APIs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Therapeutic Peptide APIs Market Facts & Figures by Country
  15. 5.5.1 Europe Therapeutic Peptide APIs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Therapeutic Peptide APIs Sales by Country (2021-2032)
  17. 5.5.3 Europe Therapeutic Peptide APIs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Russia
  23. 5.5.9 Spain
  24. 5.5.10 Netherlands
  25. 5.5.11 Switzerland
  26. 5.5.12 Sweden
  27. 5.5.13 Poland
  28. 5.6 Asia Pacific Therapeutic Peptide APIs Market Facts & Figures by Country
  29. 5.6.1 Asia Pacific Therapeutic Peptide APIs Market Size by Country: 2021 VS 2025 VS 2032
  30. 5.6.2 Asia Pacific Therapeutic Peptide APIs Sales by Country (2021-2032)
  31. 5.6.3 Asia Pacific Therapeutic Peptide APIs Revenue by Country (2021-2032)
  32. 5.6.4 China
  33. 5.6.5 Japan
  34. 5.6.6 South Korea
  35. 5.6.7 India
  36. 5.6.8 Australia
  37. 5.6.9 Taiwan
  38. 5.6.10 Southeast Asia
  39. 5.7 South America Therapeutic Peptide APIs Market Facts & Figures by Country
  40. 5.7.1 South America Therapeutic Peptide APIs Market Size by Country: 2021 VS 2025 VS 2032
  41. 5.7.2 South America Therapeutic Peptide APIs Sales by Country (2021-2032)
  42. 5.7.3 South America Therapeutic Peptide APIs Revenue by Country (2021-2032)
  43. 5.7.4 Brazil
  44. 5.7.5 Argentina
  45. 5.7.6 Chile
  46. 5.8 Middle East and Africa Therapeutic Peptide APIs Market Facts & Figures by Country
  47. 5.8.1 Middle East and Africa Therapeutic Peptide APIs Market Size by Country: 2021 VS 2025 VS 2032
  48. 5.8.2 Middle East and Africa Therapeutic Peptide APIs Sales by Country (2021-2032)
  49. 5.8.3 Middle East and Africa Therapeutic Peptide APIs Revenue by Country (2021-2032)
  50. 5.8.4 Egypt
  51. 5.8.5 South Africa
  52. 5.8.6 Israel
  53. 5.8.7 Türkiye
  54. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Therapeutic Peptide APIs Sales by Type (2021-2032)
  2. 6.1.1 Global Therapeutic Peptide APIs Sales by Type (2021-2032) & (Tons)
  3. 6.1.2 Global Therapeutic Peptide APIs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Therapeutic Peptide APIs Revenue by Type (2021-2032)
  5. 6.2.1 Global Therapeutic Peptide APIs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Therapeutic Peptide APIs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Therapeutic Peptide APIs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Therapeutic Peptide APIs Sales by Application (2021-2032)
  2. 7.1.1 Global Therapeutic Peptide APIs Sales by Application (2021-2032) & (Tons)
  3. 7.1.2 Global Therapeutic Peptide APIs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Therapeutic Peptide APIs Revenue by Application (2021-2032)
  5. 7.2.1 Global Therapeutic Peptide APIs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Therapeutic Peptide APIs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Therapeutic Peptide APIs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Therapeutic Peptide APIs Value Chain Analysis
  2. 8.1.1 Therapeutic Peptide APIs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Therapeutic Peptide APIs Production Mode & Process
  5. 8.2 Therapeutic Peptide APIs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Therapeutic Peptide APIs Distributors
  8. 8.2.3 Therapeutic Peptide APIs Customers
9 Global Therapeutic Peptide APIs Analyzing Market Dynamics
  1. 9.1 Therapeutic Peptide APIs Industry Trends
  2. 9.2 Therapeutic Peptide APIs Industry Drivers
  3. 9.3 Therapeutic Peptide APIs Industry Opportunities and Challenges
  4. 9.4 Therapeutic Peptide APIs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst